← Database
IGF-1 Analog

IGF-1 LR3

Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

A modified insulin-like growth factor with reduced binding-protein affinity and a longer half-life, used widely in cell culture; human therapeutic use is not approved.

How it works

IGF-1 LR3 is a modified, longer-lasting version of insulin-like growth factor 1 (IGF-1), a hormone that drives cell growth and division. It's used mainly as a research reagent.

Two changes — a swapped amino acid and an added segment — reduce how tightly it sticks to the binding proteins that normally hold IGF-1 in check, leaving more of it free and active. Acting on the IGF-1 receptor, it switches on growth-promoting pathways (PI3K/Akt and MAPK) more potently and for longer than natural IGF-1.

That same potent growth signaling is a double-edged sword: it's the basis for anabolic interest but also a theoretical concern, since strong, sustained growth stimulation raises proliferative and cancer-related questions. It is not approved for human use.

Mechanism · Detailed Analysis
Molecular targetAn IGF-1 receptor (tyrosine-kinase) agonist; an Arg3 substitution and N-terminal extension lower its affinity for IGF-binding proteins, leaving more free peptide active.
Signaling & downstream effectsActivates PI3K/Akt and MAPK growth signalling, with longer action than native IGF-1.
Evidence & caveatsPrimarily a cell-culture reagent. The same growth signalling underlies both anabolic interest and a theoretical proliferative/oncologic concern; not approved for human use.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.